Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel BS Switzerland 4070
- IPO Date
- Aug 20, 2003
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG, headquartered in Basel, Switzerland and founded in 1896, operates as one of the world's largest biotechnology companies and the global leader in in-vitro diagnostics; it develops and markets innovative medicines and diagnostic products across oncology, immunology, infectious diseases, ophthalmology, neuroscience, hematology, respiratory diseases, cardiovascular, renal and metabolic disorders, rare diseases, and women's health, with key pharmaceutical brands including Avastin, MabThera/Rituxan, Herceptin, Perjeta, Tecentriq, Hemlibra, Ocrevus, and Vabysmo; its diagnostics portfolio encompasses in-vitro diagnostics, point-of-care testing such as the recently FDA-cleared CLIA-waived test for Bordetella infections including whooping cough, continuous glucose monitoring systems, cell analysis, gene expression, genome sequencing, and nucleic acid purification technologies; the company serves customers worldwide through operations in more than 130 countries, with significant presence via wholly-owned Genentech in the United States and majority stake in Japan's Chugai Pharmaceutical. Roche maintains two primary segments, Pharmaceuticals and Diagnostics, targeting healthcare providers, researchers, and patients with personalized healthcare solutions that integrate data insights from clinical practice. Recent developments include a definitive merger agreement in September 2025 to acquire 89bio for up to $3.5 billion to bolster its cardiovascular, renal, and metabolic portfolio with pegozafermin for moderate to severe MASH; a $50 billion investment commitment over five years announced in April 2025 to expand U.S. R&D and manufacturing in states including Indiana, Pennsylvania, Massachusetts, and California, creating over 12,000 jobs; a $550 million expansion of its Indianapolis diagnostics site for continuous glucose monitoring by 2030; prior acquisitions such as Carmot Therapeutics in 2024, Televant Holdings for $7.1 billion in 2023, and partnerships like those with Innovent Biologics and Poseida Therapeutics; and 53 new collaboration agreements in 2024 alongside ongoing M&A firepower of about $10 billion annually.
Company News
Roche signs global licensing pact for Simcere's experimental blood cancer drug
U.S.' 'win' in the war has been choking off Iran's oil exports: David Roche
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
2 Stocks That Could Capitalize on the GLP-1 Boom
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
2 GLP-1 Stocks That Could Double Your Money by 2031
Roche Is Getting More Benefit Of The Doubt On Improving Execution
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
Roche launches two new cyclospora tests as US outbreak widens
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis